Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Duration of Antibiotic Therapy Evaluation Study in Acute Cholangitis (DATES-AC): An Open-Label, Multicenter, Randomized Non-Inferiority Trial Comparing Short-Course Versus Standard-Course Antibiotic Therapy After ERCP With Early Intravenous-to-oral Switch in Patients With Acute Cholangitis (DATES-AC)

11 de novembro de 2026 atualizado por: Seoul National University Hospital

Acute cholangitis is an infection of the bile ducts, usually caused by a blockage that prevents bile from flowing normally. It can lead to serious complications if not treated promptly. Treatment generally includes antibiotics and drainage of the blocked bile duct, usually through a procedure called endoscopic retrograde cholangiopancreatography (ERCP).

Although antibiotics are essential for treating acute cholangitis, the optimal duration of antibiotic treatment after successful bile duct drainage remains uncertain. Current guidelines generally recommend 4 to 7 days of antibiotic treatment. However, shorter treatment may be sufficient after the source of infection has been effectively controlled, potentially reducing unnecessary antibiotic exposure, side effects, hospital stay, and healthcare costs.

The purpose of this study is to determine whether a shorter course of antibiotic treatment (4 days) is as effective as the standard course (7 days) in patients with moderate to severe acute cholangitis who have undergone successful bile duct drainage.

This is a multicenter, randomized, open-label study involving adults aged 19 years or older with moderate to severe acute cholangitis. Patients whose bile duct obstruction has been successfully relieved by ERCP within one day of hospital admission and who meet the study eligibility criteria may participate. Eligible patients will be randomly assigned in a 1:1 ratio to one of two treatment groups.

The short-course group will receive antibiotics for a total of 4 days, while the standard-course group will receive antibiotics for a total of 7 days. In both groups, intravenous antibiotics will initially be given for at least 2 days. Patients who are clinically stable and able to take oral medication will be switched to oral antibiotics as early as possible. Antibiotic selection may be adjusted according to bacterial culture results and antibiotic susceptibility testing. If the initial antibiotics are found to be ineffective, or if the patient's clinical condition requires additional treatment, the antibiotics may be changed or extended to ensure patient safety.

The primary outcome is the clinical cure rate within 14 days after randomization. Cure will be assessed based on the resolution of infection-related symptoms and improvement in blood bilirubin levels, defined as a reduction of at least 50% from the initial level or normalization, without predefined treatment failure events.

Secondary outcomes include recurrence of cholangitis between days 14 and 30 among patients who initially achieve clinical cure, all-cause mortality within 30 days, total duration of antibiotic use, and patient-reported health status and satisfaction with treatment. The incidence of adverse events within 14 days will also be evaluated. Additional assessments will compare hospital stay and total treatment costs between the two groups.

Participants will be followed up at approximately 14 and 30 days after randomization to assess treatment outcomes, recurrence of infection, additional antibiotic use, and safety.

This study aims to provide evidence on whether a 4-day antibiotic treatment strategy, combined with early conversion from intravenous to oral antibiotics after successful bile duct drainage, can achieve comparable treatment outcomes to the standard 7-day regimen. The findings may help establish a more appropriate antibiotic treatment strategy for patients with acute cholangitis while reducing unnecessary antibiotic exposure and its associated burden.

Visão geral do estudo

Status

Ainda não está recrutando

Condições

Intervenção / Tratamento

Descrição detalhada

  • 1. Empirical IV Antibiotics Ceftriaxone + Metronidazole
  • 2. Culture-directed IV Antibiotics Ciprofloxacin Piperacillin/Tazobactam Ertapenem Meropenem
  • 3. PO Antibiotics Cefpodoxime proxetil Amoxicillin/Clavulanate

Tipo de estudo

Intervencional

Inscrição (Estimado)

330

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Locais de estudo

    • Gyeonggi-do
      • Ansan, Gyeonggi-do, Coréia do Sul, 15355
        • Korea University Ansan Hospital
        • Contato:
      • Seongnam-si, Gyeonggi-do, Coréia do Sul, 13620
        • Seoul National University Bundang Hospital
        • Contato:
    • Seoul
      • Seoul, Seoul, Coréia do Sul, 03080
        • Seoul National University Hospital
        • Contato:
      • Seoul, Seoul, Coréia do Sul, 07061
        • Seoul Metropolitan Government Seoul National University Boramae Medical Center
        • Contato:
      • Seoul, Seoul, Coréia do Sul, 04763

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

19 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Adults aged 19 years or older.
  • Patients who voluntarily agree to participate in the study and provide written informed consent after receiving a full explanation of the study.
  • Patients who meet the diagnostic criteria for suspected or definite acute cholangitis according to the Tokyo Guidelines 2018 (TG18), regardless of whether the underlying cause is benign or malignant.
  • Patients with moderate or severe acute cholangitis according to the TG18 severity grading criteria.
  • Patients who have undergone successful biliary drainage by endoscopic retrograde cholangiopancreatography (ERCP) within one calendar day of hospital admission, resulting in relief of biliary obstruction.

Exclusion Criteria:

  • Circulatory failure requiring vasopressor support at the time of ERCP.

  • Persistent or newly developed hypothermia (body temperature below 35°C) between hospital admission and screening.

  • Patients requiring intensive care unit (ICU) treatment.

  • Use of antibiotics within 7 days before hospital admission.

  • Use of systemic antibiotics for 7 days or longer within 90 days before study enrollment for an infection unrelated to the current episode of acute cholangitis.

  • History of recurrent acute cholangitis within the previous 3 months.

  • Complex biliary strictures classified as Bismuth type II or higher.

  • Biliary obstruction of unknown cause.

  • Acute cholangitis caused by dysfunction of a distal biliary stent when the stent was inserted less than 30 days before study enrollment.

  • Complications associated with acute cholangitis present at the time of study enrollment, including acute cholecystitis, acute pancreatitis, liver abscess, or intra-abdominal abscess.

  • Presence of an infection other than acute cholangitis at the time of study enrollment.

  • Patients at high risk of infective endocarditis caused by Gram-positive bacteria, including those with prosthetic heart valves, congenital heart disease, or a previous history of infective endocarditis.

  • Complications following ERCP, including perforation, bleeding, severe post-ERCP pancreatitis, or cardiopulmonary complications related to sedation.

  • Altered upper gastrointestinal anatomy due to previous upper abdominal surgery, except for Billroth I gastrectomy.

  • Immunocompromised patients, including:

    1. Patients receiving systemic corticosteroids at a dose equivalent to prednisolone 20 mg/day or higher for at least 14 consecutive days.
    2. Patients who have received cytotoxic chemotherapy, biological agents, or immunosuppressive therapy within the previous 3 months.
    3. Patients with hematologic malignancies or a history of hematopoietic stem cell transplantation.
    4. Patients who have undergone solid organ transplantation (liver, kidney, heart, lung, etc.) and are currently receiving immunosuppressive therapy.
    5. Patients with congenital or primary immunodeficiency disorders.
    6. Patients with advanced HIV infection, defined as a CD4-positive T-cell count below 200 cells/μL.
  • Pregnant or breastfeeding women.

  • Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation in this study.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: a shorter course of antibiotic treatment

4 days of antibiotics including PO antibioitcs

Comparision of duration of antibiotics

Comparador Ativo: a standard course of antibiotic treatment

7 days of antibiotics including PO antibioitcs

Comparision of duration of antibiotics

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
the clinical cure rate within 14 days after randomization
Prazo: Within 14 days after randomization (Day 14; assessment window: Day 11-Day 18)

Cure will be assessed based on the resolution of infection-related symptoms and improvement in blood bilirubin levels, defined as a reduction of at least 50% from the initial level or normalization, without predefined treatment failure events.

Within 14 days after randomization (Day 14; assessment window: Day 11-Day 18)

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Recurrence rate of acute cholangitis
Prazo: From Day 14 to Day 30 after randomization

Recurrence of cholangitis after cure

From Day 14 to Day 30 after randomization
All-cause mortality
Prazo: Within 30 days after randomization

Death regardless of cause

Within 30 days after randomization
Patient-reported health status (EQ-5D-5L)
Prazo: Day 2 and Day 14 after randomization

Patient self reports regarding health status

Day 2 and Day 14 after randomization
Patient satisfaction with treatment (TSQM-II)
Prazo: Day 14 after randomization

Patient self reports regarding satisfaction with treatment

Day 14 after randomization
Total duration of antibiotic use
Prazo: Within 30 days after randomization

Days with antibiotics

Within 30 days after randomization
DOOR/RADAR composite outcome
Prazo: Day 30 after randomization

Scoring system regarding the treatment outcomes

Day 30 after randomization

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Hospital stays
Prazo: Within 30 days after randomization

Duration of hospital stay

Within 30 days after randomization
Total medical costs
Prazo: Within 30 days after randomization

Total medical costs for the treatment

Within 30 days after randomization

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Jaihwan Kim, Seoul National University Bundang Hospital

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de janeiro de 2027

Conclusão Primária (Estimado)

31 de dezembro de 2029

Conclusão do estudo (Estimado)

31 de dezembro de 2029

Datas de inscrição no estudo

Enviado pela primeira vez

11 de novembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

11 de novembro de 2026

Primeira postagem (Real)

17 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

17 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

11 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • SNUBH-IMGPB-2026-01

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

INDECISO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever